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ScienceDirectThree DNA polymerases — Pol a, Pol d and Pol e — are
essential for DNA replication. After initiation of DNA synthesis
by Pol a, Pol d or Pol e take over on the lagging and leading
strand respectively. Pol d and Pol e perform the bulk of
replication with very high fidelity, which is ensured by
Watson–Crick base pairing and 30exonuclease (proofreading)
activity. Yeast models have shown that mutations in the
exonuclease domain of Pol d and Pol e homologues can
cause a mutator phenotype. Recently, we identified germline
exonuclease domain mutations (EDMs) in human POLD1 and
POLE that predispose to ‘polymerase proofreading
associated polyposis’ (PPAP), a disease characterised by
multiple colorectal adenomas and carcinoma, with high
penetrance and dominant inheritance. Moreover, somatic
EDMs in POLE have also been found in sporadic colorectal
and endometrial cancers. Tumors with EDMs are
microsatellite stable and show an ‘ultramutator’
phenotype, with a dramatic increase in base
substitutions.
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Introduction
DNA polymerases are responsible for synthesis of DNA
and are essential for replication, DNA repair and genetic
recombination. DNA replication is a highly complex
process and in eukaryotes it involves multiple enzymes
including the B family polymerases Pol a, Pol d, and Pol e
Open access under CC BY license.www.sciencedirect.com [1,2]. These enzymes catalyse the polymerisation of
deoxyribonucleotides into the nascent DNA strand.
While Pol a initiates DNA synthesis, Pol d and Pol e
replace Pol a after primer extension and perform the bulk
of DNA replication. Most polymerases lack intrinsic
error-checking activity, relying on Watson–Crick base
pairing for their fidelity. However, the proofreading (exo-
nuclease) domains of Pol d and Pol e ensure that these
polymerases have a particularly low error rate, of the order
of 107 substitution mutations per base. A variety of in
vitro studies has shown that proofreading improves repli-
cation fidelity approximately 100-fold [3,4].
The Pol d and Pol e enzymes are heterotetramers in
higher eukaryotes. Both Pol d and Pol e comprise a
catalytic subunit, POLD1 and POLE respectively, and
accessory subunits (POLD2/3/4 and POLE2/3/4) that
interact with cofactors such as Proliferating Cell Nuclear
Antigen (PCNA) [5]. Both genes are ubiquitously
expressed and show high levels of evolutionary conserva-
tion. The two polymerases differ from each other
throughout most of their length, but are homologous
(23% identity, 37% similarity) over their exonuclease
domains (residues 268–471 of POLE and 304–517 of
POLD1).
Based on studies in yeast, it has been shown that Pol d and
Pol e usually replicate the leading and lagging strand
respectively [6,7]. However, it is still not fully elucidated
whether this is always the case at replication forks. Pavlov
proposed a model where Pol e starts replicating the
leading strand, but may later dissociate, and Pol d then
takes over to complete the replication [8]. A higher
mutation rate in Pol d exonuclease deficient yeast strains
compared to Pol e exonuclease-deficient strains endorses
this hypothesis [8–10].
There is substantial evidence that in addition to DNA
synthesis, Pol e and Pol d play essential roles in repair of
chromosomal DNA [8,11,12]. Pol e and Pol d are thought
to be involved in several repair pathway including nucleo-
tide excision repair (NER), ismatch repair (MMR) and
repair of double strand breaks (DSBR) [12,13].
Polymerase proofreading defects cause
mutator phenotypes
Replication fidelity has been extensively studied in yeast
and other microbes, though less is known about the
impact of proofreading-defective DNA polymerase
mutations in higher eukaryotes. The exonuclease
domain catalyses the preferential hydrolysis of non-
complementary nucleotides at the 30-terminus, and inCurrent Opinion in Genetics & Development 2014, 24:107–113
108 Cancer genomicsyeast, inactivating missense EDMs of Pol e and Pol d
cause a base substitution mutator phenotype with vari-
able severity [9,10,14–17]. It has been suggested that in
yeast, Pol e and Pol d proofread opposite strands at
defined replication origins and may proofread for each
other [6,18,19]. Data from mice with homozygous germ-
line Pole and/or Pold1 mutations at the exonuclease active
site were shown to have distinct, but overlapping tissue-
specific tumor phenotypes. Pole-mutant animals predo-
minantly had nodal lymphomas and histiocytic sarcomas,
whereas Pold1 mutants had thymic lymphomas and skin
papillomas/sarcomas. Both types of mice had intestinal
adenomas (more in Pole) and lung tumors (more in Pold1).
Double knockout animals died early from thymic lym-
phoma. Spontaneous mutations frequencies were higher
in Pole mutants than Pold1 mutants [20]. One expla-
nation could be that the fidelity of lagging strand replica-
tion is greater than that of leading strand, because post-
replicative DNA mismatch repair (MMR) preferentially
corrects lagging strand replication errors [21,22]. How-
ever, this in contrast with the data from yeast [14].
Genetic studies in proofreading-deficient, haploid yeast
strains which also carried a MMR-defect showed a syn-
thetically lethal phenotype indicating a synergistic effect
on the mutation rate of proofreading and MMR [23,24].
This was also confirmed in mouse studies where loss of
both proofreading and MMR led to embryonic lethality
[20,25]. Conversely, others have speculated that MMR
deficiency may be required for the EDM mutator phe-
notype to be manifested [26].
Germline mutations in POLD1 and POLE
cause polymerase proofreading-associated
polyposis (PPAP)
Even if replication fidelity is high, some errors always
escape proofreading and are then corrected by MMR [27].
In studies beginning in the late 1980s, it was found that
germline mutations in four MMR genes (MSH2, MLH1,
MSH6 and PMS2) were causative for the hereditary color-
ectal and other cancers that are present in Lynch syn-
drome (reviewed in [28,29]). Furthermore, somatic
silencing of MLH1 expression occurs in several cancer
types, notably CRC and endometrial cancer (EC). In
addition, bi-allelic germline MUTYH mutations predis-
pose to adenomatous colorectal polyposis and CRC
through defective base excision repair. We recently ident-
ified specific germline EDMs in POLD1 and POLE that
are causative for the development of multiple colorectal
adenomas and CRC. Since the phenotype overlaps with
those who carry germline mutations in MUTYH and the
MMR genes, we have called the disease PPAP [30,31].
Using a combination of whole-genome sequencing of
highly selected multiple adenoma patients, linkage
analysis, and studies of loss-of-heterozygosity (LOH) in
tumors, followed by replication in a large set of familial
CRC cases [31] we identified one germline mutation inCurrent Opinion in Genetics & Development 2014, 24:107–113 POLE (p.Leu424Val) and one in POLD1 (p.Ser478Asn)
that were not present in nearly 7000 UK controls or in
public databases of controls. In addition, another probably
pathogenic mutation, POLD1 p.Pro327Leu, was found in
a further patient with multiple adenomas. Patients who
carry EDMs in POLE or POLD1 show variable pheno-
types: some have tens of adenomas that do not appear to
progress rapidly to cancer, whereas others have a small
number of large adenomas or early-onset carcinomas, thus
resembling Lynch syndrome. Interestingly, female
carriers of POLD1 p.Ser478Asn have a greatly increased
risk of EC. Segregation analysis confirmed a dominant,
high-penetrance predisposition to colorectal adenomas.
Smith et al. have subsequently proposed an additional
predisposing POLE mutation outside the exonuclease
domain [32].
Although there are several single nucleotide polymorph-
isms (SNPs) located at conserved sites within the poly-
merase or exonuclease domains of POLE and POLD1,
genome-wide association studies and a few targeted stu-
dies have found no associations with cancer risk to date
[33–38]. However, a common polymorphism within
POLD3 has been found to be associated with an increased
risk of CRC in the general northern European population
[39], although the mechanism of action is unknown.
Somatic mutations in POLD1 and POLE
Until recently, several studies had suggested the presence
of pathogenic somatic DNA polymerase mutations in
cancer, but these studies were too small to show true
functionality, many cancers were MMR-deficient (and
hence had a high background mutation rate), and EDMs
were not distinguished from other polymerase mutations.
The relatively-recent Cancer Genome Atlas (TCGA)
exome sequencing project has provided the best evidence
for POLE being the target of recurrent somatic mutations in
MMR-proficient, but ‘ultramutated’ CRCs [40]. Further
analysis showed that the mutations causing the ultramu-
tator phenotype were all EDMs [31,40,41]. In the initial
TCGA cohort, there were 7 POLE non-synonymous
EDMs out of a total of 226 CRCs (3%). All of these cancers
were microsatellite-stable (i.e. prima facie having normal
MMR). Although the germline p.Leu424Val change was
absent, two recurrent changes were found, p.Val411Leu
and p.Ser459Phe. In addition a further recurrent POLE
EDM, p.Pro286Arg, was found by a different CRC exome
sequencing project [42]. No equivalent POLD1 mutations
have been reported for CRC. One possible explanation is
that Pol e and Pol d act independently in different cells and
various cancers might have differential mutational hotspots
in oncogenes and tumor suppressors that are replicated
from different polymerases [43,44].
Due to the fact that POLD1 germline mutations predispose
to EC, we looked for somatic POLE and POLD1 mutations
in sporadic ECs. We found POLE EDMs in about 7%www.sciencedirect.com
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Mutation spectra (upper) and numbers (lower) in exome sequence data from TCGA project colorectal cancers of three types. Note that MSI+ is used
synonymously with MMR-deficient.of cancers, including some previously detected in CRCs
and one mutation affecting the exonuclease active site.
Similar to CRC, POLE mutations in ECs were associated
with an ultramutator, but microsatellite-stable phenotype,
characterised by an excess of substitution mutations [45].
As for CRC, there were no recurrent POLD1 EDMs in ECs.
TCGA EC project had similar findings [46].
Mechanisms of polymerase EDM-driven
tumorigenesis
Structural data strongly suggest that the POLE and POLD1
EDMs impair polymerase proofreading. Mapping of the
reported mutations onto a hybrid structure of yeast DNA
polymerase (3iay) and T4 polymerase shows that they
mostly lie along the DNA-binding pocket of the exonu-
clease domain [31]. POLE p.Leu424Val and POLD1
p.Ser478Asn pack together at the interface between two
helices that form the base of the exonuclease active site.
The most common somatic POLE mutation (p.Arg286His)
localises to the DNA binding pocket adjacent to the
exonuclease active site, probably perturbing the structure
of the DNA binding pocket. Data from the equivalent
residue mutation, p.Pro123Leu, in T4 bacteriophage
that produces a strong mutator phenotype confirm thiswww.sciencedirect.com hypothesis [47]. POLE amino acid 297 interacts with
exonuclease active site residue 275, and mutations here
would probably alter the active site conformation. POLE
residue 411, however, is not predicted to interact with
DNA or catalytic site residues, suggesting that the
increased mutation rate may result from secondary effects
on the binding pocket. Hypermutation is, in summary, a
very plausible consequence of POLE and POLD1 EDMs.
Exome and targeted sequencing data clearly show the
mutation spectra of tumors with POLE and POLD1 EDMs
[31,40,48]. Compared to POLE-wild type tumors,
EDM-tumors have an increased tendency for somatic base
substitutions of all types, typically with about 5000 sub-
stitutions in the coding regions alone (Figure 1).
C:G > T:A changes generally remain the most common,
but there is a particular increase in the proportion of
G:C > T:A and A:T > C:G transversions. Since
p.Pro286Arg mutant tumors show a much stronger bias
towards transversions than cancers with p.Val411Leu,
there is considerable evidence that specific POLE
mutations have different effects on the somatic mutation
spectrum. It is of note that somatic mutations secondary to
defective proofreading tend to occur at sites flanked by anCurrent Opinion in Genetics & Development 2014, 24:107–113
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Figure 2
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DNA polymerase mutations in cancer Heitzer and Tomlinson 111A base on the ‘‘positive’’ DNA strand, rather than by T, G or
C. The causes for this observation are currently unknown,
although lower helix ‘melting’ temperatures of A:T tracts
are a plausible contributing factor. Notably, in CRCs with
EDMs, the spectrum and/or frequency of known driver
mutations is unusual (Figure 2). Recurrent mutations are
frequently observed in the known CRC driver genes, but
these are often of types and at positions other than the
common hotspots. Examples include nonsense changes at
codon 1114 of APC, 1322 of MSH6 and 213 of TP53, and
missense mutations at codons 117 and 146 of KRAS and 88 of
PIK3CA [31,49]. Some of these mutations, such as KRAS
p.Lys117Asn occur adjacent to oligo(A) tracts and hence at
putative hypermutable sites in a proofreading-deficient
background. We speculate that such mutations might be
functionally suboptimal with respect to the ‘classical’
mutations, such as those at KRAS codons 12 and 13, yet
are tolerated because the ultramutator cancer can acquire
additional, advantageous mutations rapidly; we have termed
this the ‘mini-driver’ or ‘polygenic’ model of tumorigenesis.
However, other recurrent mutations, such as PIK3CA
p.Arg88Gln, do not occur in at A:T-rich context. Perhaps
these ‘atypical’ PIK3CA mutations are more selectively
advantageous than classical PIK3CA mutations, such as
codons 545 or 1047, in the context of POLE deficiency.
The data also suggest that somatic POLE mutations occur
very early during colorectal tumorigenesis, because the
frameshift mutations found often at APC in unselected
CRCs are not seen in tumors with EDMs.
POLE and POLD1 may not to act as classical tumor
suppressor genes. Enzyme loss-of-function mutations are
thought unlikely to be pathogenic, since for proofreading
can fail, successful polymerisation must have occurred first.
Another point against a classical tumor suppressor model is
the fact that only a minority of tumors with POLE or
POLD1 EDMs show LOH or other inactivating mutations
that could act as ‘second hits’. On the other hand, data from
mice only indicate a mutator phenotype and increased
frequency of tumor formation when Pole mutations are
homozygous [20]. Overall, we can certainly envisage a
situation in which the pathogenic EDMs are selectively
haploinsufficient, but we also note that somatic MSH2 and
MSH6 mutations secondary to the EDM are common
(Figure 2) and may contribute to tumorigenesis.
Perspectives
Although mutations in the exonuclease domain of POLD1
and POLE have previously been described in yeast and
mouse models, the identification of germline and somatic(Figure 2 Legend) Mutations in colorectal cancer driver genes in the 17 POLE
the following: (i) bi-allelic mutations are shown for putative tumor suppressor g
chance of being pathogenic has been performed on a gene-by-gene basis 
considered pathogenic, for CTNNB1, only mutations affecting the exon 3 ph
highly atypical but potentially pathogenic mutations may therefore not be sh
shown are highly likely to be passengers, especially missense changes in gen
presence of two mutations does not necessarily imply that these are bi-alle
www.sciencedirect.com mutations that drive tumorigenesis in humans is a recent
finding. However, the consequences of polymerase
EDMs are not yet clear and further analysis will be
needed to understand how these mutations contribute
to tumorigenesis. We do not know how proofreading fails
or why the resulting mismatch is not repaired by either a
wildtype copy of POLE or POLD1 or by MMR. There is
additionally intriguing speculation that patients with
POLE-mutant CRCs and ECs have superior survival to
those with other patients, perhaps as a result of the
general or specific mutation burden conferred by the
ultramutator phenotype. That same burden might also
make those ultramutator cancers sensitive to mutation-
inducing or DNA repair-blocking therapies. Finally, we
emphasise that although pathogenic polymerase EDM
cancers form a rare subtype of tumor apparently restricted
to the colorectum and endometrium, there is no reason to
regard them as an unimportant group. On the contrary,
fine-scale classification of cancers using molecular and
other methods is likely to form the basis of improved
patient management in the future.
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